CAJ | 학술논문

目的：探讨阿霉素联合顺铂对骨肉瘤肺转移的临床疗效和安全性。方法选取72例骨肉瘤术后肺转移患者，随机分为观察组和对照组。对照组仅接受顺铂化疗，观察组采用阿霉素联合顺铂化疗。治疗后，比较两组患者的临床疗效，生存情况和不良反应的发生情况，并检测和比较两组患者治疗前后血清TNF-α、IL-2水平。结果对照组的总有效率为66.7％，观察组为86.1％，较对照组显著升高（P<0.05）；对照组与观察组的疾病控制率分别为78.8％、94.4％，观察组显著高于对照组（P<0.05）；观察组2年和3年生存率分别为70.4％、41.7％，均显著高于对照组（P<0.05）。两组患者不良反应发生率的差异无统计学意义（P>0.05）。化疗后两组患者的血清TNF-α、IL-2水平均较化疗前明显升高（P<0.05），且观察组的TNF-α、IL-2水平均明显高于对照组（P<0.05）。结论阿霉素联合顺铂的双联化疗方案可能通过增强机体的细胞免疫功能提高骨肉瘤肺转移的疗效，且安全性高。
목적：탐토아매소연합순박대골육류폐전이적림상료효화안전성。방법선취72례골육류술후폐전이환자，수궤분위관찰조화대조조。대조조부접수순박화료，관찰조채용아매소연합순박화료。치료후，비교량조환자적림상료효，생존정황화불량반응적발생정황，병검측화비교량조환자치료전후혈청TNF-α、IL-2수평。결과대조조적총유효솔위66.7％，관찰조위86.1％，교대조조현저승고（P<0.05）；대조조여관찰조적질병공제솔분별위78.8％、94.4％，관찰조현저고우대조조（P<0.05）；관찰조2년화3년생존솔분별위70.4％、41.7％，균현저고우대조조（P<0.05）。량조환자불량반응발생솔적차이무통계학의의（P>0.05）。화료후량조환자적혈청TNF-α、IL-2수평균교화료전명현승고（P<0.05），차관찰조적TNF-α、IL-2수평균명현고우대조조（P<0.05）。결론아매소연합순박적쌍련화료방안가능통과증강궤체적세포면역공능제고골육류폐전이적료효，차안전성고。
Objective To explore the clinical efficacy and safety of adriamycin combined with cisplatin in treatment of postop-erative osteosarcoma patients with lung metastasis. Methods The selected 72 postoperative osteosarcoma patients with lung me-tastasis were divided randomly into observation group and control group. Patients in control group were treated only with cisplatin, while those in observation group were given adriamycin combined with cisplatin. Clinical curative effect, survival time, adverse reaction and serum levels of TNF-αand IL-2 before and after treatment were compared between the two groups. Results The total effective rate of the observation group (86.1%) was higher than that of the control group (66.7%), and so was the disease con-trol rate, which was 78.8%in control group but 94.4%in observation group (P<0.05). Moreover, the 2-year and 3-year survival rates were respectively 0.4%and 41.7%in the observation group, both significantly higher than in the control group (P<0.05). No statistically significant difference in adverse reactions was found between the two groups (P>0.05). After chemotherapy, the levels of TNF-αand IL-2 were increased obviously in both groups as compared with before chemotherapy (P<0.05), and they were all significantly higher in observation group than in control group (P<0.05). Conclusion Adriamycin combined with cisplatin could have better clinical effects for osteosarcoma patients with lung metastasis through enhancing immunity function.